Answers are grounded in this paper and cite their sources.
Analyzes metabolomic differences in immunologically distinct type 1 diabetes subgroups, suggesting implications for personalized treatment.
Introduction and Objective: The concept of endotypes, disease subgroups with distinct pathomechanisms, offers a framework to explain biological and therapeutic response variability in T1D. We previously identified two age-independent, immunologically distinct T1D subgroups. Subgroup 1 exhibited elevated plasma cytokine/chemokine levels, increased circulating Th1 T-cells, and a better therapeutic response to anti-CD20. Subgroup 2 had elevated levels of plasma microRNAs and a better therapeutic response to CTLA4-Ig that was associated with reductions in central memory T-cells and preservation of regulatory T-cells. Here, we analyzed plasma metabolomic profiles of these two subgroups. Methods: A cohort of individuals with new onset T1D were recruited (n=47, age=11.6 years, male=53%). Participants were assigned to subgroups using an established plasma-induced transcription assay and classification analyses with 97% accuracy. Untargeted plasma metabolomics utilized liquid chromatography-tandem mass-spectrometry. Pathway analysis utilized IPA. Results: Subgroup 1 exhibited elevated levels of pro-inflammatory liver-conjugated secondary bile acids (BAs), glycodeoxycholate and taurolithocholate, and reduced gut microbiota-derived protective secondary BAs, ursodeoxycholate and isoursodeoxycholate, compared to Subgroup 2 (FC>1.5; BH p<0.05). Subgroup 1 showed activation of inflammatory and tissue damage pathways including hepatic fibrosis and cytokine signaling (LPS, TNF, NFKB), but inhibition of homeostasis (LXR/RXR) and metabolic PPAR pathways, and cholesterol and BA regulators (INSIG1, ATP8B1, CYP7B1, and FOXA3) relative to subgroup 2 (-log(BH) p>3, Zscore>2). Conclusion: These findings extend previously defined subgroup differences, with BA dysregulation as a key feature. Given the dependence of BA homeostasis on liver-gut microbiota interactions, these results suggest the presence of a putative liver-gut-pancreas axis that may contribute to biological heterogeneity in T1D and warrants further mechanistic investigation.
No takes yet. Share an insight, caveat, or question.
Bedrat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: